1. Home
  2. DCTH vs CERS Comparison

DCTH vs CERS Comparison

Compare DCTH & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$16.31

Market Cap

578.4M

Sector

Health Care

ML Signal

HOLD

Logo Cerus Corporation

CERS

Cerus Corporation

HOLD

Current Price

$2.57

Market Cap

585.1M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCTH
CERS
Founded
1988
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
578.4M
585.1M
IPO Year
2015
1996

Fundamental Metrics

Financial Performance
Metric
DCTH
CERS
Price
$16.31
$2.57
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$22.00
N/A
AVG Volume (30 Days)
686.8K
2.0M
Earning Date
05-07-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
107.53
27.27
EPS
0.04
N/A
Revenue
N/A
$51,326,000.00
Revenue This Year
$24.54
$19.95
Revenue Next Year
$33.15
$8.84
P/E Ratio
$412.00
N/A
Revenue Growth
N/A
30.68
52 Week Low
$8.12
$1.17
52 Week High
$17.42
$3.47

Technical Indicators

Market Signals
Indicator
DCTH
CERS
Relative Strength Index (RSI) 59.15 42.11
Support Level $9.98 $2.37
Resistance Level $17.42 $2.68
Average True Range (ATR) 0.45 0.12
MACD -0.19 -0.01
Stochastic Oscillator 30.65 9.76

Price Performance

Historical Comparison
DCTH
CERS

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

About CERS Cerus Corporation

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.

Share on Social Networks: